(DRRX) - Get Report

jumped 5.7% to $3.70 after investment research firm Susquehanna Financial Group initiated coverage of the stock with a positive rating.

Citigroup downgraded


(AZN) - Get Report

to a hold rating from a buy, sending shares 1.3% lower to $61.35. Citigroup also downgraded generic drugmaker

Endo Pharmaceuticals

(ENDP) - Get Report

from a buy rating to a hold, with a price target of $34. Shares fell 1.4% to $31.24.

Abraxis BioScience


named a chief operating officer and a leadership team for its pharmaceutical products division. Frank Harmon, former head of global operations will become COO and Thomas H. Silberg will assume the role of president of the pharmaceuticals business. Shares rose 0.5% to $25.10.

Other movers included


(ACAM) - Get Report

, whose shares lost 8.5% to $5.08,

Seattle Genetics

(SGEN) - Get Report

, up 0.5% to $4.44 and


(KERX) - Get Report

, down 1.6% to $13.06.

King Pharmaceuticals


rose 1.6% to $16.52,



was up 6.5% to $10.05,

Neose Technologies

(NTEC) - Get Report

added 2.5% to $2.43,

Human Genome Sciences


gained 2.9% to $11.40, and

Forest Laboratories


was up 4.3% to $47.97.